VASCULAR BREAKTHROUGHS


Associated tags: Health, Vascular Breakthroughs, Physician, Diagnosis, Pharmaceutical industry, Vascular disease, FACS, Research, Medical imaging, Patient, RVT, Clinical trial, Safety, VASCULAR BREAKTHROUGHS, Foot, Light, Biotechnology, Twilight anesthesia, Medicare Physician Group Practice (PGP) Demonstration, Food and Drug Administration

Vascular Breakthroughs, LLC, and Vascular Care Connecticut Announce First New England Enrollment into the Novel DEXTERITY Clinical Trials of Local Anti-Inflammatory Therapy to Improve Outcomes of Deep Vein Thrombosis Therapy

Retrieved on: 
Wednesday, March 9, 2022
General Health, Health, Professional Services, Small Business, Clinical Trials, DVT, Safety, Clinical trial, Incidence, Patient, Physician, Compliance, Inflammation, Research, FACS, LLC, Vascular disease, Health, Multimedia, Bullfrog, Vein, Method, COVID-19, Environment, RVT, Deep vein thrombosis, Disease, Diagnosis, Pharmaceutical industry, Medical imaging, Vascular Breakthroughs, Vascular Care Connecticut, VASCULAR BREAKTHROUGHS, VASCULAR CARE CONNECTICUT

These trials, sponsored by Mercator MedSystems, Inc., are testing the delivery of an anti-inflammatory steroid to the tissue surrounding veins affected by deep vein thrombosis, or DVT.

Key Points: 
  • These trials, sponsored by Mercator MedSystems, Inc., are testing the delivery of an anti-inflammatory steroid to the tissue surrounding veins affected by deep vein thrombosis, or DVT.
  • Clinical trials through Vascular Breakthroughs are ongoing at Vascular Care Connecticut.
  • Vascular Care Connecticut is committed to the prevention, diagnosis, and treatment of vascular disease.
  • Vascular Care Connecticut brings together decades of experience to offer unparalleled care in Connecticut.

Dr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster

Retrieved on: 
Tuesday, January 11, 2022
Medical Supplies, Health, Medical Devices, Surgery, Other Health, Cardiology, Biotechnology, Light, Patient, Foot, Research, Clinical trial, FACS, Twilight anesthesia, Safety, Medicare Physician Group Practice (PGP) Demonstration, RVT, Leg, Health, Â, IDE, Vascular disease, Diagnosis, Multimedia, Food and Drug Administration, Sale, Food, Hospital, FDA, Physician, Medical imaging, Pharmaceutical industry, Dentistry, The Vascular Care Group, Vascular Breakthroughs, THE VASCULAR CARE GROUP, VASCULAR BREAKTHROUGHS

The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D.

Key Points: 
  • The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D.
  • View the full release here: https://www.businesswire.com/news/home/20220110005905/en/
    Dr. Stephen J. Hoenig, The Vascular Care Group Leominster (Photo: Business Wire)
    The procedure was part of an investigational device exemption (IDE) trial called DETOUR2 Continued Access (NCT04625660), sponsored by Endologix LLC.
  • "This is an impressive achievement for both Dr. Hoenig and The Vascular Care Group, said Dr. Paul Gagne, founder of Vascular Breakthroughs, the clinical trials research organization supporting Dr. Hoenig.
  • The Vascular Care Group (TVCG) is a growing group practice committed to the prevention, diagnosis, and treatment of vascular disease.